Sirtris’ new chemical entities (NCEs), SIRT1 activators, are structurally unrelated to resveratrol and up to 1,000 fold more potent.  One of the company’s NCEs will enter human safety trials in the first half of this year.

In preclinical studies, the NCEs lower glucose and improve insulin sensitivity in animal models of Type 2 Diabetes.  This occurs in key metabolic tissues, including liver, muscle, and fat.

As observed in calorie restriction and with resveratrol, the NCEs increase mitochondrial biogenesis and hold promise for treating diseases of aging such as Type 2 Diabetes.